Chardan Capital Has Strong Outlook for SABS FY2025 Earnings
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Research analysts at Chardan Capital raised their FY2025 earnings estimates for shares of SAB Biotherapeutics in a research note issued on Tuesday, April 1st. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share of ($2.65) for the year, up from their […]
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Research analysts at Chardan Capital raised their FY2025 earnings estimates for shares of SAB Biotherapeutics in a research note issued on Tuesday, April 1st. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share of ($2.65) for the year, up from their […]
